Maria Paez de la Cadena

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6375832/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities. IUBMB Life, 2021, 73, 761-773.	3.4	8
2	Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer. Diagnostics, 2020, 10, 437.	2.6	7
3	CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context. Disease Markers, 2020, 2020, 1-10.	1.3	12
4	Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial. Scientific Reports, 2020, 10, 5679.	3.3	11
5	Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+cancer stem cells subsets. Biology Open, 2019, 8, .	1.2	25
6	A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples. Clinical Epigenetics, 2018, 10, 53.	4.1	44
7	Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units. Scientific Reports, 2017, 7, 41151.	3.3	13
8	Evaluation of an automated commercial ELISA method for calprotectin determination in pleural fluid. Clinical Chemistry and Laboratory Medicine, 2017, 55, e172-e174.	2.3	5
9	A simple electroelution method for rapid protein purification: isolation and antibody production of alpha toxin from <i>Clostridium septicum</i> . PeerJ, 2017, 5, e3407.	2.0	7
10	Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis. BMC Cancer, 2017, 17, 823.	2.6	36
11	Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer. Scientific Reports, 2016, 6, 26703.	3.3	12
12	Serum Calprotectin, CD26 and EGF to Establish a Panel for the Diagnosis of Lung Cancer. PLoS ONE, 2015, 10, e0127318.	2.5	22
13	Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. SpringerPlus, 2015, 4, 171.	1.2	30
14	Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma. Clinica Chimica Acta, 2015, 448, 193-194.	1.1	3
15	Proteomics for discovery of candidate colorectal cancer biomarkers. World Journal of Gastroenterology, 2014, 20, 3804.	3.3	62
16	Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease. Scientific Reports, 2014, 4, 3999.	3.3	18
17	Postoperative Serum Levels of sCD26 for Surveillance in Colorectal Cancer Patients. PLoS ONE, 2014, 9, e107470.	2.5	17
18	Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer. BMC Cancer, 2013, 13, 543.	2.6	11

#	Article	IF	CITATIONS
19	Decreased Expression of Alpha-L-Fucosidase Gene FUCA1 in Human Colorectal Tumors. International Journal of Molecular Sciences, 2013, 14, 16986-16998.	4.1	23
20	Levels of PEDF in Pleural Effusions from Lung Adenocarcinoma and Benign Disease Patients. Disease Markers, 2013, 34, 425-430.	1.3	1
21	Changes on the Caco-2 Secretome through Differentiation Analyzed by 2-D Differential In-Gel Electrophoresis (DIGE). International Journal of Molecular Sciences, 2012, 13, 14401-14420.	4.1	22
22	Fast human serum profiling through chemical depletion coupled to gold-nanoparticle-assisted protein separation. Talanta, 2012, 100, 239-245.	5.5	28
23	Potential of soluble CD26 as a serum marker for colorectal cancer detection. World Journal of Clinical Oncology, 2011, 2, 245.	2.3	36
24	Selection of putative colorectal cancer markers by applying PCA on the soluble proteome of tumors: NDK A as a promising candidate. Journal of Proteomics, 2011, 74, 874-886.	2.4	16
25	The role of phenotypic plasticity on the proteome differences between two sympatric marine snail ecotypes adapted to distinct micro-habitats. BMC Evolutionary Biology, 2010, 10, 65.	3.2	23
26	Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer, 2010, 10, 333.	2.6	27
27	Soluble CD26 Levels and Its Association to Epidemiologic Parameters in a Sample Population. Disease Markers, 2009, 27, 311-316.	1.3	12
28	Soluble CD26 levels and its association to epidemiologic parameters in a sample population. Disease Markers, 2009, 27, 311-6.	1.3	8
29	Proteomic Comparison between Two Marine Snail Ecotypes Reveals Details about the Biochemistry of Adaptation. Journal of Proteome Research, 2008, 7, 4926-4934.	3.7	40
30	Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. International Journal of Biochemistry and Cell Biology, 2007, 39, 529-540.	2.8	27
31	Improvements in the search for potential biomarkers by proteomics: Application of principal component and discriminant analyses for two-dimensional maps evaluation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 849, 251-260.	2.3	22
32	Mutation identification and characterization of a Taiwanese patient with fucosidosis. Journal of Human Genetics, 2007, 52, 553-556.	2.3	14
33	Acetyl- and Butyrylcholinesterase Activities Decrease in Human Colon Adenocarcinoma. Journal of Molecular Neuroscience, 2006, 30, 51-54.	2.3	22
34	Differential Expression of Serum Clusterin Isoforms in Colorectal Cancer. Molecular and Cellular Proteomics, 2006, 5, 1647-1657.	3.8	50
35	(46) Cholinesterase activity and enzyme components in healthy and cancerous human colorectal sections. Chemico-Biological Interactions, 2005, 157-158, 429-430.	4.0	11
36	Application of Relative Warp Analysis to the Evaluation of Two-Dimensional Gels in Proteomics:Â Studying Isoelectric Point and Relative Molecular Mass Variation. Journal of Proteome Research, 2005. 4. 1318-1323.	3.7	5

#	Article	IF	CITATIONS
37	Clinical Interest of the Combined Use of Serum CD26 and Alpha-L-Fucosidase in the Early Diagnosis of Colorectal Cancer. Disease Markers, 2004, 19, 267-272.	1.3	22
38	Concanavalin A chromatography coupled to two-dimensional gel electrophoresis improves protein expression studies of the serum proteome. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 803, 337-343.	2.3	30
39	Purification of human alphafucosidase precursor expressed in as a glutathione S-transferase fusion protein. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 786, 7-15.	2.3	7
40	Preoperative Serum Alpha- <i>L</i> -Fucosidase Activity as a Prognostic Marker in Colorectal Cancer. Oncology, 2003, 64, 36-45.	1.9	17
41	Lectin isolation and detection of N-glycoproteins bearing sialic acid and L-fucose residues in human colorectal mucosa and in adenocarcinoma biopsies. International Journal of Oncology, 2002, 20, 367.	3.3	Ο
42	Activity and properties of α-l-fucosidase are dependent on the state of enterocytic differentiation of HT-29 colon cancer cells. International Journal of Biochemistry and Cell Biology, 2002, 34, 1291-1303.	2.8	7
43	Cell surface human α-L-fucosidase. FEBS Journal, 2001, 268, 3321-3331.	0.2	33
44	Value of the Serum Alpha- <i>L</i> -Fucosidase Activity in the Diagnosis of Colorectal Cancer. Oncology, 2000, 59, 310-316.	1.9	49
45	Nonradioactive immunoquantification of $\hat{I}\pm$ -l-fucosidase protein in human colon tissues. Journal of Proteomics, 1996, 31, 39-47.	2.4	3
46	Comparative studies of two acid β-galactosidases from rabbit and bovine kidney. Kidney International, 1989, 35, 1295-1299.	5.2	3
47	The effect of a transfected c-myc proto-oncogene on cellular differentiation. Molecular Immunology, 1988, 25, 1129-1132.	2.2	3
48	Purification and Characterization of Acid \hat{l}^2 -D-Galactosidase from Rabbit Spleen. Journal of Biochemistry, 1988, 104, 66-71.	1.7	4
49	Heterogeneity of acid β-galactosidase from rabbit kidney. International Journal of Biochemistry & Cell Biology, 1987, 19, 685-691.	0.5	1
50	Properties and kinetics of a neutral β-galactosidase from rabbit kidney. Biochimie, 1986, 68, 251-260.	2.6	12
51	Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. Oncology Reports, 0, , .	2.6	4